NEWS IN BRIEF

Novo Nordisk and Signet collaborate to deliver quats to India

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/AvigatorPhotographer)
(Image: Getty/AvigatorPhotographer)
Novo Nordisk announced a distribution agreement that will see quats delivered by Signet to the healthcare industry in India, as well as Bangladesh and Sri Lanka.

As part of its role in the agreement, Novo Nordisk Pharmatech will manufacture various quaternary ammonium compounds (quats) for Signet Chemical Corporation.

Signet, an India-based company focused on the excipient market, will then deliver the products to its markets in South Asia.

Harish Shah, managing director of Signet, commented on the collaboration: “We are pleased to be associated with Novo Nordisk Pharmatech which is the leading supplier of quats to the pharmaceutical and biopharmaceutical markets. Novo Nordisk Pharmatech’s FeF quats complement our existing portfolio of excipients used especially for ophthalmic, nasal and topical dosage forms.”

Novo Nordisk currently produces Benzalkonium Chloride, Cetrimide and Cetyl Trimethyl Ammonium Bromide quats, with the active pharmaceutical ingredients (APIs) manufactured at its site based in Koege, Denmark.

“We are very happy to work with Signet as our distribution partner for pharmaceuticals. Novo Nordisk Pharmatech’s FeF quats products fit perfectly with Signet’s wide range of excipients enabling the customers to take advantage of these synergies. We wish to give the best service to our customers and the local pharma team of Signet are experts in working with customers to support their product development,” ​said Steve Profit, sales and marketing director at Novo Nordisk Pharmatech.

At the time of publishing, Signet had not responded to a request for comment.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars